Genfit (GNFT)

• Market cap: $182M
• 1 day: 0.00%
• 5 days: -4.20%
• 1 month: -7.36%
• 3 months: -34.12%
• 6 months: -16.28%
• Year to date: -4.70%
• 1 year: -2.67%
• 5 years: -82.40%
• 10 years: -83.54%

About: Genfit SA is a biotechnology company focused on metabolic and inflammatory diseases, with a particular focus on the liver and gastroenterology. The company's research and development activity relies on its expertise in modulating gene expression through nuclear receptors. Genfit utilizes acquisitions, strategic alliances, and licensing agreements in order to fund the further development of its products. It has one segment the research and development of innovative medicines and diagnostic solutions, the marketing of which depends on the success of the clinical development phase.

Employees: 167

Fund manager confidence

Based on 2024 Q3 regulatory filings by fund managers ($100M+ AUM)

57% more capital invested

Capital invested by funds: $296K [Q2] → $465K (+$169K) [Q3]

0.01% less ownership

Funds ownership: 0.16% [Q2] → 0.16% (-0.01%) [Q3]

43% less funds holding

Funds holding: 7 [Q2] → 4 (-3) [Q3]

50% less repeat investments, than reductions

Existing positions increased: 1 | Existing positions reduced: 2

100% less first-time investments, than exits

New positions opened: 0 | Existing positions closed: 3

Research analyst outlook

1 Wall Street Analyst provided 1 year price targets over the past 3 months

• Low target: $13 256% upside
• Avg. target: $13 256% upside
• High target: $13 256% upside

1 analyst rating

• positive: 1 100%
• neutral: 0 0%
• negative: 0 0%

HC Wainwright & Co. Ed Arce 54% 1-year accuracy 82 / 151 met price target

256% upside $13

Buy Reiterated

11 Oct 2024